Journal of the American Society of Nephrology
2008 JASN IMPACT FACTOR 7.505 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KUMAGAI, J.
Right arrow Articles by TSUCHIYA, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KUMAGAI, J.
Right arrow Articles by TSUCHIYA, S.
J Am Soc Nephrol 10:2407-2411, 1999
© 1999 American Society of Nephrology

BRIEF COMMUNICATIONS

Relationship between Erythropoietin and Chronic Heart Failure in Patients on Chronic Hemodialysis

JUNKO KUMAGAI*, NORIAKI YORIOKA*, HIDEKI KAWANISHI{dagger}, MISAKI MORIISHI{dagger}, YUTAKA KOMIYA{dagger}, YUKITERU ASAKIMORI{dagger}, NAOKO TAKAHASHI{dagger} and SHINICHIRO TSUCHIYA{dagger}

* Second Department of Internal Medicine, Hiroshima University School of Medicine, Hiroshima, Japan.
{dagger} Tsuchiya General Hospital, Hiroshima, Japan.

Correspondence to Dr. Noriaki Yorioka, Second Department of Internal Medicine, Hiroshima University School of Medicine, 1-2-3 Kasumi Minami-ku Hiroshima 734-8551, Japan. Phone: + 81 82 257 5196; Fax: + 81 82 255 7360; E-mail: nyorioka{at}mcai.med.hiroshima-u.ac.jp

Abstract

Abstract. In the present study, the relationship between the blood erythropoietin level and cardiac function was investigated in 15 patients on chronic hemodialysis who developed chronic heart failure. Another 45 patients without cardiac dysfunction were selected as a control group that was matched for gender, age, and the duration of dialysis. The erythropoietin level was 256.3 ± 481.8 mU/ml in the heart failure group, which was significantly higher than that in the control group (17.0 ± 10.0 mU/ml, P <0.01). Eight of the 15 patients in the heart failure group maintained a hematocrit of more than 30% without receiving recombinant human erythropoietin therapy, whereas 29 of the 45 patients in the control group required erythropoietin. In the heart failure group, the erythropoietin level was significantly correlated with the levels of atrial natriuretic peptide and brain natriuretic peptide (P < 0.01). These results suggest that heart failure can increase the erythropoietin level in proportion to the severity of cardiac dysfunction, even in patients on long-term dialysis.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
Y. Tanaka, N. Joki, and H. Hase
History of acute coronary events during the predialysis phase of chronic kidney disease is a strong risk factor for major adverse cardiac events in patients initiating haemodialysis
Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2917 - 2923.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. M. Mancini, S. D. Katz, C. C. Lang, J. LaManca, A. Hudaihed, and A.-S. Androne
Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure
Circulation, January 21, 2003; 107(2): 294 - 299.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673